ST香雪：公司高度重视TAEST16001的临床价值与市场潜力，正全力推进确证性临床试验筹备阶段工作

Core Viewpoint - The company emphasizes the clinical value and market potential of its new drug TAEST16001 and is actively advancing the preparatory phase of confirmatory clinical trials [2]. Group 1 - The company is committed to keeping investors informed about the clinical progress of TAEST16001 and the status of its pre-restructuring efforts [2]. - The company plans to disclose updates regarding the new drug development and pre-restructuring progress in accordance with information disclosure regulations [2]. - Investors are encouraged to pay attention to the company's announcements for further details [2].